TABLE 3.

Use of supportive care interventions across all LOTs.

	Patients with ES‐SCLC (N = 1239)
Eligible for transfusions, n (%)
RBC (Hb <8 g/dL)	404 (32.6)
Platelet (platelets <10,000/μL)	46 (3.7)
RBC and/or platelet	418 (33.7)
Supportive care utilization, n (%)
G‐CSF a	1112 (89.7)
ESAs b	302 (24.4)
IV volume expansion	646 (52.1)
G‐CSF, ESAs, and/or IV volume expansion	1165 (94.0)
G‐CSF administrations c , mean (SD) [median]	5.7 (6.8) [4]

Abbreviations: ESA, erythropoiesis‐stimulating agent; ES‐SCLC, extensive‐stage small cell lung cancer; G‐CSF, granulocyte colony‐stimulating factor; Hb, hemoglobin; IV, intravenous; LOT, line of therapy; RBC, red blood cell; SD, standard deviation.

^a Includes filgrastim (including biosimilars), TBO‐filgrastim, pegfilgrastim (including biosimilars), and sargramostim.

^b Includes epoetin alfa (and biosimilar).

^c Count of unique administration days for G‐CSF among all patients.